secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001104659-24-001155
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond provides 2024 milestones: Phase 2 data for BDTX-1535 in NSCLC expected Q3; cash into Q2 2025
--------------------------------------------------------------------------------

- FDA feedback enables Phase 2 first-line cohort for BDTX-1535 in non-classical EGFR mutant NSCLC; Fast Track granted for second-line C797S.
- Phase 2 results for second/third-line EGFR mutant NSCLC expected Q3 2024; Phase 1 and window-of-opportunity GBM data expected Q2 2024.
- Phase 1 results for BDTX-4933 in KRAS mutant NSCLC expected Q4 2024.
- Existing cash, cash equivalents and investments expected to fund operations into Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465924001155/0001104659-24-001155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465924001155/tm241770d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-001155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer